NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Glycomine

Glycomine

Private
San Carlos, CaliforniaHealthcare & Life Scienceshttps://www.glycomine.com/

Last Round

Series C

Apr 16, 2025

Total Funding Raised

$228M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Glycomine is a biopharmaceutical company that develops orphan drugs aimed at treating rare metabolic disorders and protein misfolding through innovative replacement therapies and targeted intracellular delivery systems.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyrare diseasesubstrate replacement therapyenzyme replacement therapyorphan drugcongenital disorders of glycosylationCDGlipid nanoparticlesdrug developmentclinical stage biotechprecision medicinebiopharmaclinical trialsgenetic disorder

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Glycomine Comps

Public and private peers based on sector, stage, and business model.

Glycomine comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Glycomine Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CApr 16, 2025
Series BJun 23, 2021
Series BAug 7, 2019
Series ANov 16, 2016

Key People

Founding team and executive leadership

Geoffrey Hird

Chief Technology Officer

Executive Team

Glycomine Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors grew 63% MoM, from 1.3K to 2.2K.

  • Apr 16, 2025

    $115M round raised

Glycomine Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Glycomine Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Glycomine's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Carlos, California
Employee Range26
Year Founded2015
Last FundingApr 16, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.